Literature DB >> 15379770

Psoriatic arthritis.

Dafna D Gladman1.   

Abstract

Although there is still some controversy about the existence of psoriatic arthritis as a specific form of inflammatory arthritis associated with psoriasis, epidemiological, and clinical studies support the unique features of psoriatic arthritis. Because of lack of diagnostic or classification criteria, the disease has been thought of as uncommon. Over the past several decades, it has become clear that the disease leads to serious disability and even increased mortality. Traditional medications have not been effective in preventing the progression of joint damage. New medications, including biologics, have emerged with the potential to control the inflammation and arrest the progression of joint damage. Copyright 2004 Blackwell Publishing, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15379770     DOI: 10.1111/j.1396-0296.2004.04038.x

Source DB:  PubMed          Journal:  Dermatol Ther        ISSN: 1396-0296            Impact factor:   2.851


  16 in total

1.  Prevalence of patient-reported comorbidities in early and established psoriatic arthritis cohorts.

Authors:  Majed Khraishi; Don MacDonald; Emmanouil Rampakakis; Julie Vaillancourt; John S Sampalis
Journal:  Clin Rheumatol       Date:  2011-02-02       Impact factor: 2.980

2.  Obesity, waist circumference, weight change and the risk of psoriasis in US women.

Authors:  S Kumar; J Han; T Li; A A Qureshi
Journal:  J Eur Acad Dermatol Venereol       Date:  2012-10-12       Impact factor: 6.166

Review 3.  Inflammation, atherosclerosis, and psoriasis.

Authors:  David Siegel; Sridevi Devaraj; Anupam Mitra; Siba P Raychaudhuri; Smriti K Raychaudhuri; Ishwarlal Jialal
Journal:  Clin Rev Allergy Immunol       Date:  2013-04       Impact factor: 8.667

4.  Coping with arthritis is experienced as a dynamic balancing process. A qualitative study.

Authors:  Kjersti Grønning; Borghild Lomundal; Hege Svean Koksvik; Aslak Steinsbekk
Journal:  Clin Rheumatol       Date:  2011-09-03       Impact factor: 2.980

5.  Validity, reliability, and sensitivity-to-change properties of the psoriatic arthritis screening and evaluation questionnaire.

Authors:  Patrick Lee Dominguez; M Elaine Husni; Elizabeth W Holt; Stephanie Tyler; Abrar A Qureshi
Journal:  Arch Dermatol Res       Date:  2009-07-15       Impact factor: 3.017

6.  Validation of the Toronto Psoriatic Arthritis Screen II (TOPAS II) questionnaire in a Turkish population.

Authors:  Mehmet Tuncay Duruöz; Canan Şanal Toprak; Fırat Ulutatar
Journal:  Rheumatol Int       Date:  2017-11-07       Impact factor: 2.631

7.  Validation of the Toronto Psoriatic Arthritis Screen II (ToPAS II) questionnaire in a Brazilian population.

Authors:  Rafaela Silva Guimaraes Gonçalves; Georgia Alves Pereira; Emerson de Andrade Lima; Thiago Henrique Fernandes Martins; José Otamir Andrade Junior; Jonas Braynner Carvalho; Henrique Ataíde Mariz; Andrea Tavares Dantas; Angela Luzia Branco Pinto Duarte
Journal:  Clin Rheumatol       Date:  2020-11-16       Impact factor: 2.980

Review 8.  Does treatment of psoriasis reduce the risk of cardiovascular disease?

Authors:  Sarah Churton; Liza Brown; Thuzar M Shin; Neil J Korman
Journal:  Drugs       Date:  2014-02       Impact factor: 9.546

Review 9.  Adalimumab in dermatology.

Authors:  Pawel Traczewski; Lidia Rudnicka
Journal:  Br J Clin Pharmacol       Date:  2008-07-11       Impact factor: 4.335

10.  Functional role of IL-22 in psoriatic arthritis.

Authors:  Anupam Mitra; Smriti K Raychaudhuri; Siba P Raychaudhuri
Journal:  Arthritis Res Ther       Date:  2012-03-14       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.